211 related articles for article (PubMed ID: 10491434)
1. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
Yarbrough WG; Buckmire RA; Bessho M; Liu ET
J Natl Cancer Inst; 1999 Sep; 91(18):1569-74. PubMed ID: 10491434
[TBL] [Abstract][Full Text] [Related]
2. Requirement of cyclin E-Cdk2 inhibition in p16(INK4a)-mediated growth suppression.
Jiang H; Chou HS; Zhu L
Mol Cell Biol; 1998 Sep; 18(9):5284-90. PubMed ID: 9710613
[TBL] [Abstract][Full Text] [Related]
3. Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a.
Baumgartner R; Fernandez-Catalan C; Winoto A; Huber R; Engh RA; Holak TA
Structure; 1998 Oct; 6(10):1279-90. PubMed ID: 9782052
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
Fåhraeus R; Laín S; Ball KL; Lane DP
Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
[TBL] [Abstract][Full Text] [Related]
5. Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6.
Noh SJ; Li Y; Xiong Y; Guan KL
Cancer Res; 1999 Feb; 59(3):558-64. PubMed ID: 9973200
[TBL] [Abstract][Full Text] [Related]
6. Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.
Cammett TJ; Luo L; Peng ZY
J Mol Biol; 2003 Mar; 327(1):285-97. PubMed ID: 12614625
[TBL] [Abstract][Full Text] [Related]
7. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
Foster JS; Henley DC; Bukovsky A; Seth P; Wimalasena J
Mol Cell Biol; 2001 Feb; 21(3):794-810. PubMed ID: 11154267
[TBL] [Abstract][Full Text] [Related]
8. Structural characterization of the tumor suppressor p16, an ankyrin-like repeat protein.
Boice JA; Fairman R
Protein Sci; 1996 Sep; 5(9):1776-84. PubMed ID: 8880901
[TBL] [Abstract][Full Text] [Related]
9. Structural consequences of tumor-derived mutations in p16INK4a probed by limited proteolysis.
Zhang B; Peng ZY
Biochemistry; 2002 May; 41(20):6293-302. PubMed ID: 12009890
[TBL] [Abstract][Full Text] [Related]
10. Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
Becker TM; Rizos H; Kefford RF; Mann GJ
Clin Cancer Res; 2001 Oct; 7(10):3282-8. PubMed ID: 11595726
[TBL] [Abstract][Full Text] [Related]
11. Regulation of CDK7-carboxyl-terminal domain kinase activity by the tumor suppressor p16(INK4A) contributes to cell cycle regulation.
Nishiwaki E; Turner SL; Harju S; Miyazaki S; Kashiwagi M; Koh J; Serizawa H
Mol Cell Biol; 2000 Oct; 20(20):7726-34. PubMed ID: 11003668
[TBL] [Abstract][Full Text] [Related]
12. Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.
Ceha HM; Nasser I; Medema RH; Slebos RJ
Biochem Biophys Res Commun; 1998 Aug; 249(2):550-5. PubMed ID: 9712735
[TBL] [Abstract][Full Text] [Related]
13. An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4.
Li J; Joo SH; Tsai MD
Biochemistry; 2003 Nov; 42(46):13476-83. PubMed ID: 14621993
[TBL] [Abstract][Full Text] [Related]
14. p16INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells.
Sandhu C; Peehl DM; Slingerland J
Cancer Res; 2000 May; 60(10):2616-22. PubMed ID: 10825132
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A.
Fåhraeus R; Paramio JM; Ball KL; Laín S; Lane DP
Curr Biol; 1996 Jan; 6(1):84-91. PubMed ID: 8805225
[TBL] [Abstract][Full Text] [Related]
16. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts.
Alcorta DA; Xiong Y; Phelps D; Hannon G; Beach D; Barrett JC
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):13742-7. PubMed ID: 8943005
[TBL] [Abstract][Full Text] [Related]
17. Frequent deregulation of p16 and the p16/G1 cell cycle-regulatory pathway in neuroblastoma.
Diccianni MB; Omura-Minamisawa M; Batova A; Le T; Bridgeman L; Yu AL
Int J Cancer; 1999 Jan; 80(1):145-54. PubMed ID: 9935245
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a.
Russo AA; Tong L; Lee JO; Jeffrey PD; Pavletich NP
Nature; 1998 Sep; 395(6699):237-43. PubMed ID: 9751050
[TBL] [Abstract][Full Text] [Related]
19. Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through molecular dynamics simulations.
Villacañas O; Pérez JJ; Rubio-Martínez J
J Biomol Struct Dyn; 2002 Dec; 20(3):347-58. PubMed ID: 12437373
[TBL] [Abstract][Full Text] [Related]
20. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
